Navigation Links
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
Date:1/6/2014

ttp://clinicaltrials.gov/show/NCT01684150">http://clinicaltrials.gov/show/NCT01684150

Epizyme retains all U.S. rights to EPZ-5676 and has granted Celgene an exclusive license to EPZ-5676 outside of the United States. Epizyme is working with Abbott to develop a companion diagnostic to identify MLL-r patients. Additional information about Epizyme's partnerships is available here: www.epizyme.com/about-us/partnerships/

About Epizyme's Collaboration with GSK
In January 2011, Epizyme entered into a collaboration and license agreement with GSK to discover, develop and commercialize novel small molecule HMT inhibitors directed to three targets from Epizyme's product platform. Additional information about the GSK collaboration is available here: www.epizyme.com/about-us/partnerships/.

About EPZ-6438 and Epizyme's Collaboration with Eisai
Epizyme is developing EPZ-6438, a small molecule inhibitor of EZH2 created with our proprietary product platform, for the treatment of non-Hodgkin lymphoma patients who have an oncogenic (cancer-causing) point mutation in EZH2. In many human cancers, misregulated EZH2 enzyme activity results in misregulation of genes that control cell proliferation—without these control mechanisms, cancer cells are free to grow rapidly.

In June 2013, Epizyme initiated a Phase 1/2 clinical trial of EPZ-6438 in patients with advanced solid tumors or with relapsed or refractory B-cell lymphoma. This program is currently in the dose escalation phase. The company believes EPZ-6438 is the second HMTi to enter human clinical development, following Epizyme's DOT1L inhibitor, EPZ-5676.

Additional information about this program, including clinical trial information, may be found here: http://clinicaltria
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
2. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
3. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
6. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
7. Advanced Biofuels USA's Joanne Ivancic Recognized as One of Top 100 People in the BioEconomy by Biofuels Digest
8. Westchase Neck Injury Chiropractor is Now Offering the Newest Advanced Care Treatments for Injury and Chronic Pain, Courtesy of Elan Wellness Center
9. ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
10. New Ocean Sensing and Monitoring Brings Tutorial Approach to Latest Advances
11. Phoenix Research Labs Partners with Voxeleron to Advance Technology for Eye Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , , , , , ... for examining , regulatory promoter and enhancer sequences ... cases, the element under investigation (promoter, enhancer) is cloned , ... subsequently , used to transfect cells. Quantification of ...
... , , , , , ... , , , , ... is an essential step in some of the most innovative , ... the cloning of mammals, and vaccination against cancer. Compared to the , ...
... , , , Note: Genomic DNA is fragile. ... Use suitable large-bore pipet tips or equipment when , pipetting genomic ... Place a 1 cm tail sample into a ... be stored at 20C. To minimize possible cross-contamination, , ...
Cached Biology Technology:Genetic Reporter Systems 2Genetic Reporter Systems 3Genetic Reporter Systems 4Principles and applications of electrical cell fusion 2Principles and applications of electrical cell fusion 3Principles and applications of electrical cell fusion 4Principles and applications of electrical cell fusion 5Mouse Tail Genomic DNA Isolation Protocol(1) 2
(Date:7/10/2014)... everyday household items such as washing machines could hold ... new study has claimed., As part of an EPSRC ... including those from the University of Exeter, have shown ... replicated in the natural world to help restock declining ... in essence a built-in feedback control mechanism to maintain ...
(Date:7/10/2014)... Consuming a whole fresh avocado with either an ... A carotenoid (alpha- and beta-carotene) absorption and conversion of ... according to new research (1) published in ... Vitamin A is involved in reproductive health and growth ... and has antioxidant properties. Provitamin A carotenoids, like alpha- ...
(Date:7/10/2014)... 2014Women in the West African nation Burkina Faso ... option. Sayana Press has the potential to increase ... health system and in communities by combining a ... (depot medroxyprogesterone acetate)with the BD Uniject injection system. ... African countries expected to begin introducing Sayana Press ...
Breaking Biology News(10 mins):Feedback control could be key to robust conservation management 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... Researchers at the University of Granada (UGR) have studied the ... known population of Polygala balansae in Europe, a ... which was previously thought to be exclusive to Morocco. The ... and included on the list of threatened species. In ...
... taking non-oral and oral hormonal contraceptives were at highest ... study of female German medical students published today in ... women taking non-hormonal contraceptives were at lowest risk for ... "Sexual problems can have a negative impact on both ...
... change is happening today, a Kansas State University professor ... forest and grassland ecosystems. Kendra McLauchlan, assistant professor ... Foundation CAREER Award to examine contrasts in vegetation history ... nitrogen cycling and other ecosystem properties. McLauchlan is the ...
Cached Biology News:Polygala balansae, a new bush to Europe, at risk of extinction in Spain 2Hormonal contraceptives associated with higher risk of female sexual dysfunction 2Hormonal contraceptives associated with higher risk of female sexual dysfunction 3K-State professor using NSF award to study the impact of nitrogen deposition on global change 2